Primary objectives of ONWARDS 1 and 6 trials with once-weekly insulin icodec achieved

Danish diabetes care giant Novo Nordisk (NOV: N) today announced positive headline results from the main phases of ONWARDS 1 (52 weeks) and ONWARDS 6 (26 weeks) Phase IIIa trials with once-weekly insulin icodec, edging the firm’s shares up 1.35 to 779.9 kroner.

ONWARDS 1 is a Phase IIIa, 78-week efficacy and safety treat-to-target trial investigating once-weekly insulin icodec versus insulin glargine U100 (insulin glargine) – marketed by Sanofi (Euronext: SAN) as Lantus, both in combination with non-insulin anti-diabetic treatment, in 984 insulin-naïve people with type 2 diabetes.

The trial achieved its primary endpoint of demonstrating non-inferiority in reducing HbA1c at week 52 with insulin icodec compared to insulin glargine.